Equities

Aclaris Therapeutics Inc

Aclaris Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.56
  • Today's Change-0.07 / -2.66%
  • Shares traded628.50k
  • 1 Year change-46.16%
  • Beta0.2287
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Aclaris Therapeutics Inc grew revenues 5.03% from 29.75m to 31.25m while net income improved from a loss of 86.91m to a smaller loss of 88.48m.
Gross margin53.53%
Net profit margin-136.65%
Operating margin-170.99%
Return on assets-18.47%
Return on equity-25.83%
Return on investment-20.87%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Aclaris Therapeutics Inc fell by 5.40m. However, Cash Flow from Investing totalled 46.22m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 78.33m for operations while cash generated from financing totalled 26.71m.
Cash flow per share-0.5072
Price/Cash flow per share--
Book value per share1.82
Tangible book value per share1.82
More ▼

Balance sheet in USDView more

Aclaris Therapeutics Inc uses little or no debt in its capital structure.
Current ratio7.03
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.